Serina Therapeutics (NYSEAMERICAN:SER) Insider Randall Moreadith Sells 6,500 Shares of Stock

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) insider Randall Moreadith sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $2.86, for a total transaction of $18,590.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Randall Moreadith also recently made the following trade(s):

• On Thursday, March 19th, Randall Moreadith sold 39,000 shares of Serina Therapeutics stock. The stock was sold at an average price of $2.50, for a total transaction of $97,500.00.
• On Monday, February 2nd, Randall Moreadith sold 6,500 shares of Serina Therapeutics stock. The shares were sold at an average price of $3.03, for a total transaction of $19,695.00.
• On Wednesday, January 28th, Randall Moreadith sold 6,500 shares of Serina Therapeutics stock. The shares were sold at an average price of $3.57, for a total transaction of $23,205.00.
• On Thursday, January 22nd, Randall Moreadith sold 2,500 shares of Serina Therapeutics stock. The shares were sold at an average price of $2.95, for a total transaction of $7,375.00.
• On Wednesday, January 21st, Randall Moreadith sold 2,000 shares of Serina Therapeutics stock. The stock was sold at an average price of $3.00, for a total value of $6,000.00.

Serina Therapeutics Stock Up 24.7%

Shares of SER stock opened at $3.03 on Thursday. The stock has a market capitalization of $32.69 million, a P/E ratio of -1.62 and a beta of 1.25. Serina Therapeutics, Inc. has a 52-week low of $1.22 and a 52-week high of $7.92. The stock has a fifty day simple moving average of $2.13.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its earnings results on Wednesday, March 25th. The company reported ($0.31) EPS for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.